Skip to main content
SpringerLink
Log in

Fidaxomicin tops in CDI infection in Ireland and Belgium

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. van Engen A, et al. Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infections (Cdi) Also Known as C. Difficile-Associated Diarrhoea (Cdad) in Ireland. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PIN69, 2 Nov 2013.

  2. Lamotte M, et al. The Cost-Utility of Fidaxomicin as Compared to Current Standard Treatment in the Management of Clostridium Difficile Infections in Belgium. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PGI35, 2 Nov 2013.

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fidaxomicin tops in CDI infection in Ireland and Belgium. PharmacoEcon Outcomes News 692, 9 (2013). https://doi.org/10.1007/s40274-013-0895-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0895-3

Search

Navigation